The stealth was brief, but the ambition is not.
Breakthru Medicine stepped into public view Wednesday with $60 million in Series A funding and a pitch that might sound familiar to anyone tracking the oncology dealmaking frenzy: multi-modality platform, treatment-resistant tumors, molecular glues. Yet the roster of backers suggests something caught their attention—even in a market where billion-dollar partnerships have become almost mundane.
Leading the round is Dave Morehead, chief investment officer of Baylor University's endowment, who was named Institutional Investor's 2025 Endowment CIO of the Year. He's joined by Fred Eshelman, the veteran who built PPD into a clinical research powerhouse before selling it and turning to early-stage ventures. Rounding out the marquee names: Mark Gergen, who until recently ran Poseida Therapeutics and now chairs Breakthru's board. Others participated but weren't named—a not-uncommon hedge in competitive sectors.
For a company that only formally registered in Arizona last August, it's the kind of investor lineup that turns heads.
Three Shots on Goal
Phoenix isn't exactly known as a biotech hub, but Breakthru's founding team knows the oncology circuit well enough that geography may matter less than pedigree. CEO Steve Potts previously launched OncoMyx Therapeutics, raising roughly $75 million before it quieted down. Before that, he ran global patient identification for entrectinib at Ignyta—a small-molecule cancer drug that became part of Roche's $1.7 billion buyout in 2017. Not every bet wins, but Potts has seen both sides of the table.
His chief scientific officer, Mark Mulvihill, brings a specialty that's become something of a gold rush in pharma circles: molecular glues. He worked on non-degrader glues at Warp Drive Bio, a now-shuttered biotech whose programs reportedly influenced what Revolution Medicines is pursuing today. Add stops at HiberCell and OSI Pharmaceuticals, and you have someone who's been around the block on hard-to-drug targets.
Chief Medical Officer Kimberly Perez worked on the Kadcyla ADC launch at Genentech—one of the success stories in antibody-drug conjugates—before stints at Puma Biotechnology and OncBioMune. The trio claims involvement in more than a dozen therapies that made it to approval or late-stage trials, many tagged with FDA Breakthrough Therapy Designation. It's the kind of résumé that venture investors circle in red.
Breakthru's platform spans three modalities: small molecules, next-generation ADC payloads, and those molecular glues—non-degraders, specifically, which work differently than the degrader glues that have grabbed most of the headlines. The company says it's targeting what it calls "hardest-to-drug" proteins in solid tumors. Details on specific programs remain locked down, though materials shared with investors late last year indicated the first small molecule could enter human testing in early 2027. Animal data, they said, showed "industry-leading efficacy." (Caveat emptor: nearly every preclinical pitch makes that claim.)
Why Now, Why This?
Molecular glues have become a magnet for big pharma dollars. Last November, Novartis inked a $150 million upfront deal with Monte Rosa Therapeutics. In May, Genentech handed Orionis Biosciences a pact worth over $2 billion in potential milestones. ADCs, meanwhile, have their own momentum—AstraZeneca, Daiichi Sankyo, and others are racing to refine payloads and linkers that can deliver chemotherapy directly to tumor cells without wrecking everything else.
Breakthru is betting it can stand out in both arenas. Whether that's realistic depends on data no one outside the company has seen yet. The fact that Morehead, who oversees billions for one of the country's largest endowments, is willing to place chips on this table suggests he's seen something. Or perhaps just that he believes this team can execute—always a safer bet than novel science alone.
The company is based in Peoria, a sprawling Phoenix suburb better known for master-planned communities than life sciences. An informal scientific advisory board, pieced together from LinkedIn mentions by Mulvihill, includes oncologists Thai Ho, David Hong, Mitesh Borad, and Sunil Sharma. No formal roster has been published, and Breakthru declined to comment on pipeline specifics beyond what's in the January 29 announcement.
The Long Game
Breakthru's seed round was undisclosed, so the total capital raised likely exceeds $60 million—though by how much remains anyone's guess. CB Insights pegs it at "at least" that figure, which is consultant-speak for "we don't know either."
With a clinical start date still more than a year out, the company has time to refine its pitch and perhaps court a pharma partner before burning through the Series A. In precision oncology, the exit paths are well-worn: get bought before Phase 2, or strike a fat licensing deal once proof-of-concept lands. A few rare birds make it to late-stage trials on their own. Breakthru's leadership has done both in past lives.
For now, the Phoenix biotech is one more name in a swelling field of startups chasing "undruggable" targets with chemistry that five years ago seemed impossible. The difference, if there is one, may come down to whether Morehead, Eshelman, and Gergen picked the right jockeys.
They're betting they did. The rest of us will find out in 2027.
